Pravastatin 40 mg daily reduced the incidence of non-fatal MI and CHD death during a follow-up of 3.2 years, in this trial involving the 2804 elderly men and 3000 women with a history of, or risk factors for vascular disease. This trial extended the treatment strategies to elderly population.
PROSPER Trial
APEX Trial
ACTIVE A Trial
ASPEN Trial
JUPITER Trial
AFCAPS/TexCAPS Trial
Action study
Agent study